Endocrine and Metabolic Science最新文献

{"title":"Diabetic nephropathy: Pathophysiology and potential therapeutic role of plant extracts","authors":"Mehak Naseer Mir ,&nbsp;Ishfaq Ahmad Malik ,&nbsp;Rayees Ahmad Naik ,&nbsp;Sonalika Singh ,&nbsp;Aabid Rashid Hurra ,&nbsp;Zahid Ahmad Wani ,&nbsp;Rakhmat Shah ,&nbsp;Yaqoob Lone","doi":"10.1016/j.endmts.2025.100263","DOIUrl":"10.1016/j.endmts.2025.100263","url":null,"abstract":"<div><h3>Objective</h3><div>This review aims to explore the molecular mechanisms underlying diabetic nephropathy (DN), with a particular focus on the role of oxidative stress. Additionally, it evaluates the therapeutic potential of plant-based extracts rich in bioactive compounds for the management of diabetes and its associated renal complications.</div></div><div><h3>Results</h3><div>Oxidative stress is identified as a key contributor to DN pathogenesis. Several major pathways are involved, including hypoxia-inducible factor-1 (HIF-1), transforming growth factor-beta (TGF-β), mitochondrial dysfunction, renin-angiotensin-aldosterone system (RAAS) activation, and endothelial nitric oxide synthase (eNOS) uncoupling. These mechanisms collectively lead to podocyte injury, tubular damage, extracellular matrix accumulation, disrupted renal hemodynamics, and glomerular hyperfiltration. Plant-derived compounds have shown potential in modulating these pathways, thereby offering renal protective effects.</div></div><div><h3>Conclusion</h3><div>Plant-based remedies enriched with bioactive compounds represent promising adjunct therapies for managing diabetes and its renal complications. Their integration into conventional treatment regimens may provide a holistic approach to glycemic control and reduction of oxidative stress-induced kidney damage. This review underscores the importance of multifaceted therapeutic strategies targeting both metabolic dysregulation and oxidative stress to effectively prevent and manage diabetic nephropathy.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"19 ","pages":"Article 100263"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144771501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperthyroidism treatment: A brief review with recommendations","authors":"Wissal Abassi ,&nbsp;Nejmeddine Ouerghi ,&nbsp;Nidhal Jebabli ,&nbsp;Moncef Feki ,&nbsp;Anissa Bouassida ,&nbsp;Katja Weiss ,&nbsp;Beat Knechtle","doi":"10.1016/j.endmts.2025.100282","DOIUrl":"10.1016/j.endmts.2025.100282","url":null,"abstract":"<div><div>Hyperthyroidism is an endocrine disorder in which excessive levels of thyroid hormones are circulating, either because of an exogenous source such as a prescription error or excessive hormone production by the thyroid gland. The present brief review aims to summarize the current treatment options and provide a medical guide for professionals. There are many treatment options for hyperthyroidism. The choice of treatment depends on the cause and severity of the disease, the presence of contraindications to a particular treatment modality, and the patient's preference. Treating the disease will prevent long-term health problems and relieve uncomfortable symptoms. Antithyroid drugs, radioactive iodine, beta-blockers and surgery are the primary treatment options for persistent hyperthyroidism. Each therapeutic method can produce beneficial effects if used appropriately.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"19 ","pages":"Article 100282"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D regulation of cortisol through the HPA axis: A focused review","authors":"Dinara S. Kulzhanova ,&nbsp;Ainur Amanzholkyzy ,&nbsp;Sholpan Kosmuratova ,&nbsp;Arailym K. Altymova ,&nbsp;Wassim Y. Almawi","doi":"10.1016/j.endmts.2025.100275","DOIUrl":"10.1016/j.endmts.2025.100275","url":null,"abstract":"<div><div>Vitamin D has a significant influence on neuroendocrine regulation by modulating cortisol levels through hypothalamic-pituitary-adrenal (HPA) axis mechanisms. This review explores the biological mechanisms connecting vitamin D to cortisol regulation and its clinical implications beyond bone health. Vitamin D receptors are widely distributed in stress-responsive brain regions, and evidence suggests that vitamin D signaling regulates cortisol through both genomic and non-genomic pathways. Clinical findings are mixed; some studies suggest cortisol levels decrease after vitamin D supplementation in cases of obesity, depression, or inflammation, while others show minimal effects in healthy populations. This relationship varies with age and gender. Variability in study results stems from differences in research design, baseline vitamin D levels, cortisol measurement methods, and genetic polymorphisms that affect metabolism. Despite this, vitamin D acts as a modulator of the stress response, especially benefiting vulnerable groups. Future research should implement standardized protocols that consider circadian rhythms and population differences.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"19 ","pages":"Article 100275"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145095299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into the potential role of sEH inhibition in the prevention and progression of neurological disorders","authors":"Mamatha Gavisiddaiah ,&nbsp;Sumanta Kumar Goswami ,&nbsp;Manali Somanna ,&nbsp;Bruce D. Hammock ,&nbsp;Kenganora Mruthunjaya ,&nbsp;Abigail Fielding ,&nbsp;Dithu Thekkekkara ,&nbsp;Santhepete Nanjundaiah Manjula","doi":"10.1016/j.endmts.2025.100277","DOIUrl":"10.1016/j.endmts.2025.100277","url":null,"abstract":"<div><div>Neurological disorders are associated with decreased blood supply to the brain, neuronal damage, oxidative stress, and inflammation. While treatments are limited, soluble epoxide hydrolase inhibitors can be useful in alleviating neurological disorders via increasing or maintaining the levels of epoxy fatty acids (EpFAs), which modulate multiple biological pathways to dilate blood vessels, protect neurones, alleviate inflammation, and reduce oxidative stress. Enzyme soluble epoxide hydrolase (sEH), with dual function, is found in multiple tissues, including the brain. It is extensively expressed in neurones, astrocytes, and CNS vasculature in the cortex and hippocampus, suggesting its significant role in neurological functions. It is a key factor in the metabolism of EpFAs, namely epoxyeicodatrienoic acids (EETs), the byproducts of arachidonic acid mediated by the P450 pathway, which are transformed into their respective diols, known as dihydroxyeicosatrienoic acids (DHETs), which are proinflammatory agents and are less potent compared to EETs. EETs suppress the generation of pro-inflammatory signalling molecules and other inflammatory mediators, aiding in the resolution of inflammation. Inhibiting sEH elevates the concentration of EETs and other structurally similar EpFAs while reducing the release of nitric oxide metabolites and pro-inflammatory cytokines. EETs act as potential endothelial-derived hyperpolarizing factors (EDHFs), which promote vascular health through the hyperpolarization and relaxing of the vascular smooth muscle cells. The vasodilatory effect of EETs improves blood flow to the brain and other tissues, which support neuronal health and function. The elevated levels of EETs provide cytoprotection to brain cells, potentially slowing the progression of neurodegeneration. Modulating EETs by inhibiting sEH presents an emerging therapy for addressing neurological diseases. Ultimately, this review explores the influence of soluble epoxide hydrolase inhibitors in preventing the progression of neurodegenerative diseases.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"19 ","pages":"Article 100277"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145519716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of adolescent obesity with elevation of ESR: Which comes first?","authors":"Sama Atta Gitti,&nbsp;Saman SarKo Baha Al-den","doi":"10.1016/j.endmts.2025.100261","DOIUrl":"10.1016/j.endmts.2025.100261","url":null,"abstract":"<div><h3>Background</h3><div>Obesity has become a global epidemic. Several studies suggest that adipose tissue is not only an inert energy store but also an endocrine organ that communicates with the central nervous system.</div></div><div><h3>Objective</h3><div>To assess the association between erythrocyte sedimentation rate (ESR) and body mass index (BMI), age, presence of complications such as diabetes and fatty liver disease, and weight loss.</div></div><div><h3>Methods</h3><div>Fifty patients visited AL-Kindy specialized endocrinology outpatient clinic for obesity assessment. Patients were followed up for three months, and their baseline characteristics were analyzed using Student's <em>t</em>-test and chi-square test; p values &lt;0.005 were considered significant.</div></div><div><h3>Results</h3><div>The highest ESR values were observed in the age group of 10–14 years (mean ESR: 56.4 mm/h), followed by the 15–19 year group (mean ESR: 51.7 mm/h). The mean ESR in male patients was significantly higher than that in female patients (53.09 mm/h vs. 25.71 mm/h). Approximately 80 % of the patients with fatty liver disease had a high ESR. The patients were prescribed a calorie-restricted diet for three months; the mean BMI at the end of the study was 31.25 ± 1.21 kg/m², and the mean ESR was 20.32 ± 30.2 mm/h compared with the baseline ESR of 35.8 ± 42.5 mm/h.</div></div><div><h3>Conclusion</h3><div>The study findings indicate that a higher BMI is associated with higher ESR levels. The highest ESR values were observed in the age group of 10–14 years (mean 56.4 mm/h), suggesting that systemic inflammation may precede or accelerate the development of obesity during adolescence.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"19 ","pages":"Article 100261"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144614005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thymus vulgaris seed extract hampered hepatic oxidative burden and improved insulin sensitivity in obese male rats","authors":"Sherif A. Abdelmottaleb Moussa ,&nbsp;Fatma A.A. Ibrahim ,&nbsp;Marawan Abd Elbaset ,&nbsp;Fatma A. Morsy ,&nbsp;Samir W. Aziz ,&nbsp;Noha A. Abd El-Latif ,&nbsp;Sherif M. Afifi ,&nbsp;Tuba Esatbeyoglu ,&nbsp;Sayed A. El Toumy ,&nbsp;Josline Y. Salib ,&nbsp;Samir A.E. Bashandy","doi":"10.1016/j.endmts.2025.100235","DOIUrl":"10.1016/j.endmts.2025.100235","url":null,"abstract":"<div><div>Thyme, belonging to the family Lamiaceae, stands out as a noteworthy herb with diverse applications. This study investigates the impact of <em>Thymus vulgaris</em> seed extract administration on hepatic oxidative burden, insulin sensitivity, and liver function in obese rats. The <em>T. vulgaris</em>-treated groups, particularly the high-dose (400 mg/kg) group, showed substantial reductions in waist size, body weight, and BMI compared to the obese group. While reducing inflammatory markers, <em>T. vulgaris</em> seed extract supplementation demonstrated significant improvements in lipid profiles, insulin resistance, liver function, and antioxidant status. Histopathological examination of hepatic tissues confirmed the curing effects of <em>T. vulgaris</em> seed extract, as shown by improvements in hepatic architecture and a reduction in the deleterious changes induced by obesity. LC-MS was used to identify 32 metabolites in the seed extract of <em>T. vulgaris</em> with methoxyflavonoids as the most prevalent class. In conclusion, <em>T. vulgaris</em> seed extract administration exhibited promising anti-obesity effects, influencing anthropometric measures, lipid profiles, insulin resistance, liver function, and inflammatory and hepatic oxidative stress markers in obese rats. The study culminated in the potential therapeutic role of <em>T. vulgaris</em> seed in managing obesity-related complications.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100235"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"l-carnitine protects against bile acid-induced mitochondrial dysfunction and IGF-1 impairment in hepatocyte cultures","authors":"Wafa'a Alqabandi,&nbsp;Maira Alsaeid,&nbsp;Gursev Dhaunsi","doi":"10.1016/j.endmts.2025.100249","DOIUrl":"10.1016/j.endmts.2025.100249","url":null,"abstract":"<div><h3>Background and aims</h3><div>Excessive amounts of bile acids (ΒΑ) exert hepatotoxic effects. We investigated the effects of glycochenodeoxycholic acid (GCDC) on mitochondrial function and insulin-like growth factor-1 (IGF-1) activity in hepatocytes and also examined if <span>l</span>-carnitine (CRNT) has any protective role.</div></div><div><h3>Methods</h3><div>Primary hepatocyte cultures were treated with 0–100 μM GCDC with or without 5 mM <span>l</span>-carnitine (CRNT). DNA synthesis was measured by bromodeoxyuridine incorporation assay. Enzymic activities of carnitine palmitoyltransferase-1 (CPT-1), cytochrome <em>c</em> oxidase (CcO) and medium chain-acylCoA dehydrogenase (MCAD), were measured in hepatocyte homogenates. Expression of peroxisome proliferator activated receptor gamma coactivator 1-α (PGC-1α) and IGF-1 receptor (IGF-1R) was detected by RT- PCR and Western blot analysis, respectively<em>.</em></div></div><div><h3>Results</h3><div>Treatment with GCDC significantly decreased the enzymatic activity of MCAD, CPT-1 and CcO (<em>P</em> &lt; 0.01), and mitochondrial ATP content. Additionally, GCDC significantly increased malondialdehyde (MDA) levels in mitochondria and downregulated PGC-1α (<em>p</em> &lt; 0.01). Furthermore, the IGF-1-induced DNA synthesis and IGF-1R gene expression were also notably reduced in GCDC-treated hepatocytes. However, co-treatment with 5 mM CRNT markedly abrogated the GCDC-induced impairment of CcO activity and PGC-1α downregulation, while it had no effect on MCAD activity. In addition, CRNT treatment also restored the enzymatic activity of CPT-1 and the gene expression levels of IGF-1 in GCDC-treated hepatocytes (<em>p</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>GCDC-induced hepatotoxic effects could be triggered by mitochondrial dysfunction and impairment of IGF-1 activity. CRNT has potential beneficial effects against ΒΑ-induced cytotoxicity via enhancing the CPT-1 and CcO enzyme activities, and ATP production in addition to upregulation of PGC-1α and IGF-1R.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100249"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biochemical, laboratory and instrumental diagnostic indicators of early diagnosis of women with gestational diabetes","authors":"Gulchekhra Ikhtiyarova Akmalovna ,&nbsp;Gulrukh Karimova Komilovna ,&nbsp;Guljamal Arstanalievna Subanova ,&nbsp;Nilufar Navruzova Orzijonovna ,&nbsp;Nargiza Narzulloeva Sayfilloevna ,&nbsp;Feruza Oripova Shopulatovna ,&nbsp;Salimova Toxtajan Baxtiyarovna ,&nbsp;Aiganysh Zhoomartovna Rysbaeva ,&nbsp;Fakher Rahim","doi":"10.1016/j.endmts.2025.100252","DOIUrl":"10.1016/j.endmts.2025.100252","url":null,"abstract":"<div><div>Gestational diabetes (GDM) is a type of diabetes that can develop during pregnancy in women who don't have diabetes. We studied the concentration of homocysteine in the blood in two study groups - 36 healthy pregnant women and 68 pregnant women with GDM. The study included biochemical (homocysteine, glucose, creatinine, glycated hemoglobin), hormonal (leptin, C-peptide, 25 (OH) D, and methods of correlation and statistical research. According to the analysis of blood in the case histories of patients in groups, anemia was observed in an average of 61.45 % of patients. Homocysteine is a biomarker that controls the action of folic acid in the body in pregnant women, the reference values of which are in the range of 5.6–16.42 μmol/l, while in healthy women this diagnostic indicator averages 12.98 ± 0.31. The mean homocysteine value in pregnant women with GDM was 42.87 ± 2.26 μmol/l (<em>P</em> ≤ 0.001). Another specific marker in pregnant women with GDM is the study of cholecalciferol, vitamin 25(OH) D. It was found that the level of significance of the difference between the indicators in the group of pregnant women with GDM and in the control group was almost 2 times less. Based on this finding, in future studies, the predictive value of each of these indices in the occurrence of GDM can be examined. It was also found that such indices differ significantly in patients with GDM compared to the control group, although further studies in the broader population are needed to confirm this.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adrenal incidentaloma: Prevalence and evaluation. Experiences from a single health network","authors":"Mitchell Munnings ,&nbsp;Shaun Koh ,&nbsp;Christopher Gilfillan","doi":"10.1016/j.endmts.2025.100238","DOIUrl":"10.1016/j.endmts.2025.100238","url":null,"abstract":"<div><h3>Background</h3><div>Increasing utilization and sensitivity of radiological imaging has led to an increase in the detection of adrenal incidentalomas (AIs). Most AIs are non-functional benign lesions, though, exclusion of functional and/or malignant AIs is mandatory. International guidelines describe the recommended evaluation of these lesions. However, data on local adherence to such recommendations is unknown.</div></div><div><h3>Aims</h3><div>To investigate the prevalence and evaluation of AIs discovered in a metropolitan health network and compare the data with established guidelines.</div></div><div><h3>Methods</h3><div>The study involves a retrospective identification of patients over 18 years old using keyword search criteria within radiology reports from computed tomography (CT) studies performed during 2019 and 2020. Clinical notes and the electronic medical record were interrogated to gather pathology results, co-morbidities, and follow-up. Patients with a known history of active malignancy, suspected adrenal pathology, or an established history of an adrenal adenoma were excluded.</div></div><div><h3>Results</h3><div>Adrenal incidentalomas were identified in 274 patients, with a prevalence of 0.7 %. Biochemical evaluation occurred in 15.3 % of AIs, and the recommended evaluation of cortisol and catecholamine excess occurred in 8.0 % of cases. Dedicated adrenal imaging occurred in 14.6 % of cases, and 10.2 % of AIs referred to endocrinology. Benign non-functional adenoma was the most common diagnosis; however, most AIs (82.1 %) did not have a final diagnosis.</div></div><div><h3>Conclusions</h3><div>Our study demonstrates a significant gap between guideline-recommended investigation of AIs and clinical practice. A similar suboptimal investigation rate has been reported internationally, leading to a hypothesis that is not an isolated finding. These data suggest an essential area for education to improve patient care.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100238"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus","authors":"To Anh Tan Le ,&nbsp;An Viet Tran ,&nbsp;Son Kim Tran ,&nbsp;Chau Minh Tran ,&nbsp;Dang Khoa Dang Tran ,&nbsp;Duy Huu Duong ,&nbsp;Toan Hoang Ngo","doi":"10.1016/j.endmts.2025.100230","DOIUrl":"10.1016/j.endmts.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>LDL-C and non-HDL-C are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy in hypertensive patients with or without diabetes mellitus is essential.</div></div><div><h3>Objectives</h3><div>This study aims to compare the efficacy of Rosuvastatin 20 mg in controlling LDL-C and non-HDL-C in hypertensive patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.</div></div><div><h3>Results</h3><div>In hypertensive patients without diabetes (n = 54; 42.9 %), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4 %) compared to those with diabetes (n = 72; 57.1 %). After 12 weeks of Rosuvastatin 20 mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-C and non-HDL-C levels (p &lt; 0.001). The treatment targets for LDL-C were achieved by 27.8 % of diabetic patients and 20.4 % of non-diabetic patients, while the targets for non-HDL-C were achieved by 40.3 % of diabetic patients and 41.5 % of non-diabetic patients. History of stroke and coronary artery disease was significantly associated with increased LDL-C and non-HDL-C in both pre-and post-treatment in both groups.</div></div><div><h3>Conclusion</h3><div>The utilization of Rosuvastatin 20 mg has shown efficacy in ameliorating elevated LDL-C and non-HDL-C levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20 mg aids in better control of LDL-C and non-HDL-C compared to the hypertensive group with diabetes.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}